SUMMARY In a series of 59 experiments in nine duodenal ulcer patients, 24 hour intragastric acidity was measured before, during, and after treatment with daily oral omeprazole. Omeprazole 10, 20 , and 30 mg/day for one week caused a 37, 90, and 97% decrease of 24 hour intragastric acidity, respectively. No further decrease of acidity was observed when the dose of omeprazole was doubled to 60 mg/day, or after a second week of treatment with 30 mg/day. One week after stopping treatment with omeprazole (14 doses) there was a significant 26% decrease of 24 hour intragastric acidity, with full recovery seven weeks later. Fasting plasma gastrin concentration was significantly raised during treatment with all doses of omeprazole. Omeprazole 30 mg/day is the optimal dose for a maximal decrease of 24 hour intragastric acidity in duodenal ulcer patients.
Omeprazole is a substituted benzimidazole compound, one of a group of dru s which inhibit the parietal cell H+,K+-ATPase. ' -This enzyme is thought to be the gastric proton pump which effects acid secretion at the parietal cell secretory membrane.
Initial studies with omeprazole have shown that it is a potent inhibitor of both basal and stimulated acid secretion in man, with a prolonged duration of action.9
Measurement of 24 hour intragastric acidity has been used successfully to observe the effects of other antisecretory drugs under conditions which approximate normal daily activity. 1 ("3 We have already reported that oral omeprazole, 30 mg/day for seven days, virtually eliminates 24 hour intragastric acidity in duodenal ulcer patients. 14 That study has been extended in the same patients to compare the effects of different doses of omeprazole, to assess the drug's duration of action, and to relate observed changes of acidity to plasma gastrin and omeprazole concentrations.
ally-proven duodenal ulceration were studied during symptomatic remission. None took any other antisecretory drug for at least two weeks before the start of each study. Their mean age was 47-4 years (range years) and their mean weight was 69*2 kg (range 56-8-85.0 kg). Five of the patients were cigarette smokers (mean 14/day).
TWENTY FOUR HOUR INTRAGASTRIC ACIDITY
The technique for measuring intragastric acidity has already been described.'014 Intragastric acidity, from 0900-0800 hours the next day, was measured by hourly aspiration of 5-10 ml of gastric contents through a nasogastric tube. The pH of the aspirates was measured to the nearest 0-01 pH unit on the bench using a combined glass electrode which was calibrated before, during and after each group of hourly measurements using buffers of pH 1-68, 4-01, and 7-00 (Radiometer, Copenhagen).
Identical meals, including beer or wine with lunch and dinner, were provided for each of the seven studies at 0915, 1115, 1315, 1615, 1915, and 2215 hours. No snacks or drinks were taken between these meals. Cigarette smoking was allowed, but the same quantity and timing was repeated during all the studies.
TREATMENT
The patients were studied before, during, and after treatment with omeprazole. The omeprazole was always taken orally 15 minutes before breakfast as enteric coated granules in a hard gelatin capsule. To encourage compliance with this once daily regimen, the patients were each provided during the study with a Casio F-85 alarm chronograph wristwatch, which has a 24 hour alarm.
The design of the study is shown in the Statistical significance of observed differences in the acidity and gastrin data was assessed by two-way analysis of variance, after logarithmic transformation of the data.
Results

INTRAGASTRIC ACIDITY DURING TREATMENT
The mean hourly intragastric H+ activity of the six patients who received each of the seven day courses of omeprazole (10, 20 , and 30 mg/day) is shown in Figure 1 . There was a dose dependent decrease of acidity. Twenty four hour intragastric H+ activity fell from 39-2±2 3 mmol/l (mean ± SEM) before treatment to 24-6±2 2 mmol/l (37% decrease), 3-9±0 9 mmol/l (90% decrease), and 1-1±0-4 mmol/ 1 (97% decrease) during treatment with omeprazole 10, 20, and 30 mg/day, respectively. The differences between each of the regimens are significant (p<0.01). Figure 2 shows each patient's decrease of 24 
PLASMA OMEPRAZOLE
After all doses of oral omeprazole there was considerable variation in the timing and level of the peak plasma omeprazole concentration. This variation is shown by the concentrations seen in eight patients after one week of treatment with omeprazole 30 mg/day (Fig. 7) .
The area under the plasma omeprazole concentration/time curve (AUC) was related to the dose of omeprazole (Fig. 8 ), but the relationship was non-linear. Mean AUC increased 3-8-fold (range 1-9-5.1, n=5) when the dose increased from 30 mg to 60 mg/day. In three patients the mean AUC did not change significantly between the seventh and fourteenth doses of omeprazole 30 mg (3-6 to 3 3 ,umol/h/l, respectively), the AUC was also related to the percentage decrease of mean 24 hour intragastric H+ activity (Fig. 9) . Omeprazole 20 mg/day caused a 90% decrease of mean 24 hour intragastric acidity. Not only was more acid present in the stomach during the morning-and the night than with omeprazole 30 mg/day, however, but there was also a return of acid 5 in the early evening. Omeprazole 20 mg/day caused a more profound and consistent decrease of acidity throughout the 24 hours (Fig. 1) with either cimetidine or ranitidine in conventional dosage regimens.13 Omeprazole 20 mg/day caused median 24 hour intragastric pH to rise from 14 to 5*0, whereas ranitidine 300 mg/day or cimetidine 1 g/day caused median pH to rise from 1*4 to 1-7 and 2.4, respectively.14 Although omeprazole 10 mg/day caused a statistically significant 37% decrease of mean 24 hour intragastric acidity, only four out of eight patients contributed to this decrease (Fig. 2) . The remaining patients did not decrease their acidity with that dose of omeprazole. Because of the variation in response observed in this study, omeprazole 10 mg/day may not be a suitable low dose for the maintenance therapy of peptic ulceration. The consistent rises of fasting plasma gastrin observed during and after treatment with omeprazole probably reflect the prolonged decrease of intragastric acidity caused by the drug. There was a significant further rise of fasting plasma gastrin concentration between the seventh and fourteenth doses of omeprazole, however, when there was no further decrease of intragastric acidity. A significant rise of serum gastrin has been observed in duodenal ulcer patients during alkalinisation of the stomach using exogenous sodium bicarbonate solution. 16 This change in gastrin was only observed when the intragastric environment was held at pH 7 for five hours.
A rise in fasting plasma gastrin concentration has been observed during treatment with either cimetidine or ranitidine.17-23 The significant rise of fasting plasma gastrin during treatment with omeprazole may be owing not only to the drug's profound antisecretory effect, but also to its prolonged duration of activity. Postprandial plasma gastrin concentration may rise during cimetidine or ranitidine treatment, when intragastric acidity is not neutralised by intragastric titration with alkali.2>26 Postprandial hypergastrinaemia during H2 blockade develops one to two hours after the meal,24 25 whereas there is a consistent rise in postprandial plasma gastrin during omeprazole treatment (Fig. 6) , due to the rise of fasting plasma 100 80. Omeprazole, taken as a capsule 15 minutes before breakfast, causes a sustained decrease of intragastric acidity, which persists after clearance of the drug from the plasma (Figs. 1 and 7 ). This continuation of omeprazole's antisecretory activity has been observed before,9 but its long duration is confirmed by the finding of a significant decrease of mean 24 hour intragastric acidity seven days after the last of 14 doses of omeprazole. The persisting decrease of intragastric acidity was seen throughout the 24 hour study, but was most marked during the basal secretion of the latter part of the night (Fig. 3) . The mechanism of this prolonged inhibition is unclear, particularly as omeprazole-induced inhibition of acid secretion is rapidly reversible in isolated guinea pig parietal cells. Omeprazole's long duration of activity could prove to be a major therapeutic benefit, as control of intragastric acidity would be sustained despite minor lapses of compliance by a patient. Eight weeks after the last dose of omeprazole intragastric acidity had returned to the pretreatment level, showing recovery of normal gastric function.
The pattern of plasma omeprazole concentration was extremely variable after the oral administration of this preparation of the drug. As omeprazole is unstable in an acid environment, the drug was protected in this study by an enteric coating. The enteric coated granules of omeprazole appear to leave the stomach with either breakfast or morning coffee, causing peak concentrations in the plasma at 1000 or 1200 hours (Fig. 7) . When 
